Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Aug;80(11):1797–1802. doi: 10.1038/sj.bjc.6690600

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

W Scheithauer 1, G V Kornek 1, M Raderer 1, M Hejna 1, J Valencak 1, J Miholic 2, E Kovats 3, F Lang 4, J Funovics 5, E Bareck 6, D Depisch 6
PMCID: PMC2363123  PMID: 10468299

Abstract

Although the novel cytidin analogue gemcitabine has shown superior anti-tumour activity than 5-fluorouracil in advanced pancreatic cancer, further improvements of therapeutic results are warranted. This goal might be achieved by combining gemcitabine with other active drugs. This trial evaluated the efficacy and tolerance of such a combination regimen with epirubicin and granulocyte colony-stimulating factor (G-CSF) in patients with metastatic disease. Seventy patients with metastatic pancreatic adenocarcinoma were enrolled in this multicentre trial. Patients received 4-weekly courses of a combination regimen consisting of epirubicin 60 mg m−2 given as intravenous bolus injection on day 1, gemcitabine 1000 mg m−2 infused over 30 min on days 1, 8 and 15, and G-CSF administered at 5 μg kg−1 day−1 subcutaneously from days 2–6 during each cycle. The efficacy of treatment was assessed by conventional measures, i.e. objective response, progression-free and overall survival, as well as by analysis of clinical benefit response (defined as ≥ 50% reduction in pain intensity, ≥ 50% reduction in daily analgesic consumption, and/or ≥ 20-point improvement in Karnofsky performance status that was sustained for ≥ 4 consecutive weeks). Of 66 patients evaluable for objective response, one achieved complete and 13 partial remissions, for an overall response rate of 21% (95% confidence interval (CI), 12–33%); 27 additional patients (41%) had stable and 25 (38%) increasing disease. The median time to progression was 3.8 months. Median survival was 7.8 months, and the probability of surviving beyond 12 months was 21.2%. Out of 60 patients with tumour-related symptoms, who were considered evaluable for clinical benefit response, 26 (43%) experienced significant palliation. The median time to achieve a clinical benefit response was 7 weeks, and its median duration was 22 weeks. Chemotherapy was well-tolerated with leukopenia/granulocytopenia representing the most common and dose-limiting side-effect. Gastrointestinal and other subjective toxicities were infrequent and generally rated minor. We conclude that the combination of gemcitabine, epirubicin and G-CSF seems to be an effective palliative treatment with only moderate toxic effects in patients with metastatic pancreatic adenocarcinoma. Our results in terms of objective and clinical benefit response, as well as survival seem to suggest an advantage over gemcitabine-monotherapy, though this remains to be confirmed in a randomized trial. © 1999 Cancer Research Campaign

Keywords: pancreatic cancer, chemotherapy, gemcitabine, epirubicin

Full Text

The Full Text of this article is available as a PDF (83.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. R., Bernstein L., Pike M. C. Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics. 1982 Jun;38(2):407–416. [PubMed] [Google Scholar]
  2. André T., Lotz J. P., Bouleuc C., Azzouzi K., Houry S., Hannoun L., See J., Esteso A., Avenin D., Izrael V. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol. 1996 Feb;7(2):173–178. doi: 10.1093/oxfordjournals.annonc.a010545. [DOI] [PubMed] [Google Scholar]
  3. Burris H. A., 3rd, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413. doi: 10.1200/JCO.1997.15.6.2403. [DOI] [PubMed] [Google Scholar]
  4. Casper E. S., Green M. R., Kelsen D. P., Heelan R. T., Brown T. D., Flombaum C. D., Trochanowski B., Tarassoff P. G. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12(1):29–34. doi: 10.1007/BF00873232. [DOI] [PubMed] [Google Scholar]
  5. GEHAN E. A. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961 Apr;13:346–353. doi: 10.1016/0021-9681(61)90060-1. [DOI] [PubMed] [Google Scholar]
  6. Hertel L. W., Boder G. B., Kroin J. S., Rinzel S. M., Poore G. A., Todd G. C., Grindey G. B. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res. 1990 Jul 15;50(14):4417–4422. [PubMed] [Google Scholar]
  7. Kornek G., Raderer M., Schenk T., Pidlich J., Schulz F., Globits S., Tetzner C., Scheithauer W. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma. Cancer. 1995 Oct 15;76(8):1356–1362. doi: 10.1002/1097-0142(19951015)76:8<1356::aid-cncr2820760810>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  8. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  9. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]
  10. Ribas A., Albanell J., Bellmunt J., Solé-Calvo L. A., Bermejo B., Gallardo E., Vidal R., Vera R., Eres N., Carulla J. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol. 1996 May;14(5):1573–1580. doi: 10.1200/JCO.1996.14.5.1573. [DOI] [PubMed] [Google Scholar]
  11. Rothenberg M. L., Moore M. J., Cripps M. C., Andersen J. S., Portenoy R. K., Burris H. A., 3rd, Green M. R., Tarassoff P. G., Brown T. D., Casper E. S. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996 Apr;7(4):347–353. doi: 10.1093/oxfordjournals.annonc.a010600. [DOI] [PubMed] [Google Scholar]
  12. Schnall S. F., Macdonald J. S. Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol. 1996 Apr;23(2):220–228. [PubMed] [Google Scholar]
  13. Warshaw A. L., Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992 Feb 13;326(7):455–465. doi: 10.1056/NEJM199202133260706. [DOI] [PubMed] [Google Scholar]
  14. Wils J., Bleiberg H., Blijham G., Dalesio O., Duez N., Lacave A., Splinter T. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol. 1985 Feb;21(2):191–194. doi: 10.1016/0277-5379(85)90172-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES